• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    8/21/23 1:31:12 PM ET
    $ARQT
    $AZYO
    $CNSP
    $CPHI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $ARQT alert in real time by email

    Gainers

    • Timber Pharmaceuticals (AMEX:TMBR) stock moved upwards by 97.9% to $2.81 during Monday's regular session. Timber Pharmaceuticals's stock is trading at a volume of 17.3 million shares as of 13:31 EST. This is 3771.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $8.5 million.
    • China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 89.15% to $0.28. As of 13:31 EST, this security is trading at a volume of 116.9 million shares, making up 26232.6% of its average full-day volume over the last 100 days. The company's market cap stands at $3.9 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) stock increased by 45.48% to $0.19. The current volume of 137.4 million shares is 803.1% of Novo Integrated Sciences's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $28.7 million.
    • China Pharma Holding (AMEX:CPHI) stock rose 27.8% to $0.28. The current volume of 13.7 million shares is 3888.2% of China Pharma Holding's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $3.2 million.
    • Fortress Biotech (NASDAQ:FBIOP) stock increased by 25.74% to $10.94. As of 13:31 EST, Fortress Biotech's stock is trading at a volume of 93.5K, which is 415.2% of its average full-day volume over the last 100 days.
    • Orchestra BioMed Hldgs (NASDAQ:OBIO) shares moved upwards by 25.7% to $6.7. Orchestra BioMed Hldgs's stock is trading at a volume of 283.5K shares as of 13:31 EST. This is 357.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $239.4 million.

    Losers

    • CNS Pharma (NASDAQ:CNSP) shares fell 24.7% to $1.36 during Monday's regular session. The current volume of 338.0K shares is 72.6% of CNS Pharma's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $5.7 million.
    • Arcutis Biotherapeutics (NASDAQ:ARQT) shares fell 17.08% to $6.49. Arcutis Biotherapeutics's stock is trading at a volume of 3.2 million shares as of 13:31 EST. This is 290.6% of its average full-day volume over the last 100 days. The company's market cap stands at $399.8 million.
    • Modular Medical (NASDAQ:MODD) stock fell 15.58% to $1.03. As of 13:31 EST, Modular Medical's stock is trading at a volume of 239.8K, which is 74.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $21.7 million.
    • Frequency Therapeutics (NASDAQ:FREQ) shares decreased by 12.73% to $0.5. Trading volume for Frequency Therapeutics's stock is 333.1K as of 13:31 EST. This is 19.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $18.3 million.
    • Vivos Therapeutics (NASDAQ:VVOS) shares declined by 10.58% to $0.28. Trading volume for Vivos Therapeutics's stock is 368.2K as of 13:31 EST. This is 23.7% of its average full-day volume over the last 100 days. The company's market cap stands at $8.3 million. As per the news, the Q2 earnings report came out 3 days ago.
    • Aziyo Biologics (NASDAQ:AZYO) stock declined by 10.41% to $1.4. The company's market cap stands at $22.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ARQT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARQT
    $AZYO
    $CNSP
    $CPHI

    CompanyDatePrice TargetRatingAnalyst
    Orchestra BioMed Holdings Inc.
    $OBIO
    12/10/2025$15.00Buy
    TD Cowen
    Orchestra BioMed Holdings Inc.
    $OBIO
    8/20/2025Buy → Neutral
    BTIG Research
    Arcutis Biotherapeutics Inc.
    $ARQT
    7/25/2025$18.00Neutral
    Goldman
    Orchestra BioMed Holdings Inc.
    $OBIO
    3/20/2025$12.00Buy
    BTIG Research
    Orchestra BioMed Holdings Inc.
    $OBIO
    1/2/2025$16.00Overweight
    Barclays
    Arcutis Biotherapeutics Inc.
    $ARQT
    12/30/2024$19.00Buy
    H.C. Wainwright
    Arcutis Biotherapeutics Inc.
    $ARQT
    8/28/2024$15.00Buy
    Jefferies
    Orchestra BioMed Holdings Inc.
    $OBIO
    8/22/2024$14.00Buy
    H.C. Wainwright
    More analyst ratings

    $ARQT
    $AZYO
    $CNSP
    $CPHI
    SEC Filings

    View All

    Modular Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Modular Medical, Inc. (0001074871) (Filer)

    3/6/26 4:16:02 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form 424B4 filed by Modular Medical Inc.

    424B4 - Modular Medical, Inc. (0001074871) (Filer)

    3/4/26 11:53:43 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    SEC Form EFFECT filed by Modular Medical Inc.

    EFFECT - Modular Medical, Inc. (0001074871) (Filer)

    3/4/26 12:15:18 AM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    $ARQT
    $AZYO
    $CNSP
    $CPHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology

    ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatmentChildren ages 2-5 who achieved disease clearance and who switched to proactive twice-weekly application sustained disease control for a median duration of ~8 monthsThese results further support the Company's focus on expanding options for pediatric populations WESTLAKE VILLAGE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Pediatric Dermatology published data from the Phase 3 open-label

    3/10/26 9:00:00 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth

    WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the promotion of Mas Matsuda, JD, currently senior vice president and general counsel, to executive vice president, chief legal officer, and corporate secretary. Mr. Matsuda will continue to lead the Company's legal, compliance, and governance strategy in support of the continued growth of the Company, commercialization of the ZORYVE® (roflumilast) portfolio, and protection of the Company's intellectual property, as well as any corporate transactions. "I am

    3/5/26 9:00:00 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT

    NEW HOPE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced two presentations that will be given at the Technology Heart Failure and Therapeutics ("THT") and Cardiovascular Research Technologies ("CRT") 2026 Meetings highlighting the potential for the Company's Atrioventricular Interval Modulation Therapy ("AVIM Therapy") program in hypertensive heart disease and heart failure patients. Presentation at THT 2026Atrioventricular Interval Modulation

    3/3/26 8:00:00 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $ARQT
    $AZYO
    $CNSP
    $CPHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen initiated coverage on Orchestra BioMed with a new price target

    TD Cowen initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $15.00

    12/10/25 8:29:27 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Orchestra BioMed downgraded by BTIG Research

    BTIG Research downgraded Orchestra BioMed from Buy to Neutral

    8/20/25 8:28:57 AM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Goldman initiated coverage on Arcutis Biotherapeutics with a new price target

    Goldman initiated coverage of Arcutis Biotherapeutics with a rating of Neutral and set a new price target of $18.00

    7/25/25 9:06:04 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    $AZYO
    $CNSP
    $CPHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Technology Officer Faulkner Eric

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    3/4/26 5:02:29 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Faulkner Eric

    3 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    3/4/26 5:02:02 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer O'Loughlin Steve

    4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)

    3/4/26 5:01:43 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    $AZYO
    $CNSP
    $CPHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Hochman David P bought $20,350 worth of shares (5,000 units at $4.07), increasing direct ownership by 0.82% to 612,822 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    11/17/25 5:00:21 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Aryeh Jason bought $2,450 worth of shares (1,000 units at $2.45), increasing direct ownership by 0.93% to 108,482 units (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    9/19/25 6:57:57 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Fain Eric S bought $15,034 worth of shares (5,760 units at $2.61) (SEC Form 4)

    4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

    8/25/25 7:04:50 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care

    $ARQT
    $AZYO
    $CNSP
    $CPHI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

    12/19/23 3:40:08 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    12/15/23 5:01:31 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARQT
    $AZYO
    $CNSP
    $CPHI
    Financials

    Live finance-specific insights

    View All

    Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior yearReported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026Announced expansion of its dermatology sales force and, separately, the initiation of a targeted Arcutis commercialization effort for primary care and pediatric health care providersProduced positive op

    2/25/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference

    Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ETArcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026 WESTLAKE VILLAGE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Wednesday, February 25, 2026 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:3

    1/22/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025

    Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), t

    11/19/25 4:20:00 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $ARQT
    $AZYO
    $CNSP
    $CPHI
    Leadership Updates

    Live Leadership Updates

    View All

    Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

    WESTLAKE VILLAGE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Amit Munshi has been appointed to the Arcutis Board of Directors effective December 4, 2025, and announced the retirement of founder and long-serving Board member Bhaskar Chaudhuri, PhD. Dr. Chaudhuri will continue as a consultant for the Company. "As Arcutis looks to continue to grow in this next chapter, we are delighted to welcome Amit, an exceptional and visionary biopharmaceutical leader, to the Arcutis Board," said Frank Watanabe, president and chi

    12/8/25 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer

    Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies Dr. Osborne to guide expansion of QTORIN™ platform, including second QTORIN™ product candidate on track to be announced by year-end 2025 WAYNE, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration

    9/3/25 7:30:00 AM ET
    $ARQT
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vivos Therapeutics Adds to Management Team to Support Expansion and Growth

    LITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company"), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced the appointments of Michael (Mike) E. Bruhn as its Executive Vice President of Business Operations Integration, and Dr. Terry Jones as its new Senior Vice President of Human Resources. These hires demonstrate Vivos' commitment to the successful implementation and expansion of its new sleep testing center and direct patient treatment operations, highlighted by Vivos' recent acquisition of The Sleep Center of Nevada and Vivos' ongoing, active e

    7/30/25 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $ARQT
    $AZYO
    $CNSP
    $CPHI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Modular Medical Inc.

    SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)

    11/25/24 7:18:33 PM ET
    $MODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

    SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    11/14/24 7:50:59 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

    SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

    11/14/24 4:49:30 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care